Status:
COMPLETED
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
Lead Sponsor:
Rallybio
Conditions:
Fetal and Neonatal Alloimmune Thrombocytopenia
Eligibility:
FEMALE
18+ years
Brief Summary
A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HP...
Eligibility Criteria
Inclusion
- Pregnant women (≥ 18 years of age) who have provided informed consent for the study.
Exclusion
- Participants with prior history of FNAIT
Key Trial Info
Start Date :
March 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 10 2025
Estimated Enrollment :
14390 Patients enrolled
Trial Details
Trial ID
NCT05345561
Start Date
March 14 2022
End Date
October 10 2025
Last Update
November 6 2025
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
New Horizons Clinical Trials, LLC
Chandler, Arizona, United States, 85224
2
Zillan Clinical Research - Gardena
Gardena, California, United States, 90247
3
Yale University School of Medicine
New Haven, Connecticut, United States, 06511
4
University of Miami Miller School of Medicine
Miami, Florida, United States, 33136